Population
Type 1 and type 2 diabetic patients with early or advanced renal disease, and diabetic subjects at risk of…
Design
Review
Authors
Loading...
Supports RAS inhibition for renoprotection in diabetic nephropathy; leaves open need for updated RCTs in contemporary populations.
Aggressive antihypertensive treatment, particularly with renin-angiotensin system inhibitors, is crucial for renoprotection and mitigating vascular complications in diabetic patients.
Jandeleit‐Dahm et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: